SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Biocon informs about media release

08 Apr 2026 Evaluate

Biocon has informed that it enclosed Company Statement with respect to ‘Biocon Pharma Limited Receives U.S. FDA Approval for Dapagliflozin Tablets, 5 mg and 10 mg’. The above information will also be available on the website of the Company at www.biocon.com.

The above information is a part of company’s filings submitted to BSE.

Biocon Share Price

348.60 2.85 (0.82%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×